-
-
-
-
-
-
-
ProMIS Neurosciences raises up to $175 million in private placement
-
-
-
-
-
-
-
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
-
-
-
-
-
-
-
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
-
-
-
-
-
-
-
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
-
-
-
-
-
-
-
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
-
-
-
-
-
-
-
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
-
-
-
-
-
-
-
ProMIS Neurosciences, Inc. (PMN) Tops Q3 EPS by 7c
-
1,218,292 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

